Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Makers of Wegovy, Zepbound face competition from compounding pharmacies The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Drugs like Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) are delivering phenomenal results in a country where some 75% of adults are overweight or obese.

Zepbound is a prescription drug used for weight management and obstructive sleep apnea. While depression was not reported in studies of Zepbound, it's still something to watch out for while using ...

Warkentin and other sleep medicine experts emphasized Zepbound is not a "magic bullet" and any treatment must look at numerous factors in a person’s health.

Zepbound could benefit handsomely if an apparently planned government program is implemented.

Cigna beats investor expectations on Evernorth growth Cigna’s health insurance business is performing within expectations, even as the insurer faces persistently heightened medical costs ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans, pharmacy chains, and the federal government.

Cigna Group reaffirmed its 2025 guidance Thursday on the back of solid growth within its Evernorth businesses and limited exposure to higher costs embroiling government-backed plans. | Executives ...

Growth in Cigna's Evernorth Health Services division drove revenue, the Bloomfield, Conn., company said. Adjusted revenue in Evernorth, which offers pharmacy benefit services, increased 17%.